NDA 020866 · Veroscience
Cycloset
Bromocriptine Mesylate · Oral
Last checked: Nov 20, 2026Latest source record: Aug 17, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
May 5, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
47
13 Phase 3, 3 recruiting
FAERS reports
646
513 serious, 30 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 12, 2026.
CYCLOSET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. CYCLOSET is an ergot derivative indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Should not be used to treat type 1 diabetes or diabetic ketoacidosis. ( 1 ) Limited efficacy data in combination with thiazolidinediones. ( 1 ) Efficacy has not been confirmed in combination with insulin. ( 1 ) Limitations of Use CYCLOSET should not be used to treat type 1 diabetes or diabetic ketoacidosis. Limited efficacy data in combination with thiazolidinediones. Efficacy has not been confirmed in combination with insulin.
Mechanism: CYCLOSET contains bromocriptine mesylate, a sympatholytic, dopamine D2 receptor agonist. In patients with type 2 diabetes, timed morning administration of CYCLOSET is associated with increased insulin sensitivity and glucose disposal and reduced fasting and postprandial hyperglycemia throughout the meals of the day without raising plasma insulin levels.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 5, 2009 Original approval · Type 3 - New Dosage Form ReviewSummary Review
1 products under this application
- CYCLOSET · BROMOCRIPTINE MESYLATE EQ 0.8MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bromocriptine" as an intervention, any sponsor and status, largest first.
- Safety and Tolerability Study of Cycloset in Treatment of Type 2 DiabetesPivotal-lookingCompleted
VeroScienceIndustry
NCT00377676 · 3,095 participants · Start Jul 2004 · Primary completion Jan 2007
Drug: Cycloset; Usual Diabetes Therapy plus placebo · For: Type 2 Diabetes Mellitus
- PRolaCT - Three Prolactinoma RCTsPivotal-lookingStatus unknown
Leiden University Medical CenterAcademic, hospital or other
NCT04107480 · 880 participants (planned) · Start Jun 21, 2019 · Primary completion Mar 31, 2024
Drug: Dopamine Agonists · For: Prolactinoma; Prolactin-Producing Pituitary Tumor
Sites: Amsterdam-Zuidoost, Netherlands; Delft, Netherlands; Leiden, Netherlands
Boehringer IngelheimBoehringer Ingelheim
NCT02233023 · 705 participants · Start Jun 1998 · Primary completion Jun 2000
Drug: Pramipexole; Bromocriptine and other dopamine agonists · For: Parkinson Disease
- MOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistPivotal-lookingCompleted
Newron Pharmaceuticals SPAIndustry
NCT00605683 · 679 participants · Start Nov 2007 · Primary completion Jan 2012
Drug: Safinamide (as add-on therapy); Safinamide (as add-on therapy) and 1 more · For: Idiopathic Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Oxnard, California · 125 sites in all
- Surgical and Pharmacological Efficacy of Knosp Grade 0-2 ProlactinomaPivotal-lookingNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT06556186 · 600 participants (planned) · Start Oct 1, 2024 · Primary completion Mar 31, 2027
Drug: Bromocriptin 2.5mg, 2-3 times a day · For: Pituitary Tumor
- Study on Therapy of Non-invasive ProlactinomaPivotal-lookingStatus unknown
First Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT03353025 · 394 participants (planned) · Start Jan 1, 2016 · Primary completion Dec 31, 2025
Drug: dopamine agonist treatment · For: Prolactinoma
Sites: Guangzhou, China
- A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate TabletsPivotal-lookingRecruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07124221 · 382 participants (planned) · Start Sep 12, 2025 · Primary completion Nov 21, 2026
Drug: Cabergoline tablets; Bromocriptine mesylate tablets · For: Hyperprolactinemia
Sites: Beijing, China
- Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02172573 · 315 participants · Start Apr 1999 · Primary completion Jul 2000
Drug: Pramipexole; Bromocriptine and 2 more · For: Parkinson Disease
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea46
- drug ineffective37
- headache35
- vomiting33
- dizziness31
- pyrexia29
- fatigue28
- drug exposure during pregnancy25
- neuroleptic malignant syndrome24
- tremor22
- somnolence20
- diarrhoea19
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 30 |
| 2006 | 34 |
| 2007 | 33 |
| 2008 | 37 |
| 2009 | 15 |
| 2010 | 19 |
| 2011 | 78 |
| 2012 | 62 |
| 2013 | 16 |
| 2014 | 16 |
| 2015 | 30 |
| 2016 | 29 |
| 2017 | 30 |
| 2018 | 23 |
| 2019 | 21 |
| 2020 | 8 |
| 2021 | 16 |
| 2022 | 22 |
| 2023 | 27 |
| 2024 | 45 |
| 2025 | 14 |
| 2026 | 8 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cycloset (Bromocriptine Mesylate)
2024 spending
$2.4M
Beneficiaries
620
2,635 claims
Per beneficiary
$3,861
$5.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,948,075 |
| 2021 | $3,951,290 |
| 2022 | $3,634,070 |
| 2023 | $3,241,662 |
| 2024 | $2,394,108 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Editorial: Bromocriptine.
· Lancet 1975 · Clinical Trial
- Dopamine agents for hepatic encephalopathy.
Junker AE, Als-Nielsen B, Gluud C, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Prolactin secretion in Parkinson disease.
Eisler T, Thorner MO, MacLeod RM, et al. · Neurology 1981 · Clinical Trial, Randomized Controlled Trial
- Treatments for suppression of lactation.
Oladapo OT, Fawole B · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Hypoprolactinemia and ovarian function.
Kauppila A, Martikainen H, Puistola U, et al. · Fertil Steril 1988 · Clinical Trial, Randomized Controlled Trial
- Pharmacotherapy for sleep bruxism.
Macedo CR, Macedo EC, Torloni MR, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Veroscience
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.